

In the matter of Akash Bhudia Regulation 28 (PFD) Report.Bhudia.pdf

**Dear Miss Persaud** 

Thank you for your email dated 19/5/23 and the enclosed Regulation 28 Report (attached as reference).

Since the inquest Medica have edited the Medica Alerts policy to include a potential new diagnosis of TB as a reason to raise an urgent notification to referrers. The alert and the report should advise the referrer that a change of treatment may be required.

This new policy has been circulated to all reporters and a communication from me has highlighted the findings of the inquest to all reporters.

Medica will work with Clients to enact the Academy of Royal College/RCR Alerts guidelines 2022 as Clients wish to/are able to integrate the process locally. I note the Academy of Royal Colleges advice that 'open TB' should receive a Critical Alert. This is not a process in place in any NHS Trust to my knowledge at this time. Medica will raise Urgent Findings until Clients adjust their internal processes.

I would like to respond to the following areas of the Regulation 28 Report:

- Section 5. The CXR was reported in a way that raised the possibility of atypical pneumonia. At the time of
  reporting the CXR the reporter had no knowledge of the additional information available in the court, there were
  no red flag symptoms for TB given in the clinical request and the CXR findings could have been caused by a
  number of pathogens including TB and COVID amongst others including fungi and less common bacteria.
  Therefore, the Xray was reported in what I would consider a standard way.
- Section 5. At the time of the CXR in question, I would consider Akash to have been under the care of his GP. My
  comment regarding a clinical team was meant to indicate primary, secondary and tertiary care if there is an
  element of active management/follow up. IRMER 2017 regulations place onus on the referrer to read and act
  appropriately on imaging reports of studies they have initiated.
- Section 5. There is an agreed Medica Alerts policy and an agreed Medica/Barts Alerts policy in place now and at the time of the reporting of the CXR. This did not overtly specify a need to alert TB.

Yours sincerely

MB ChB (Hons), BSc (Hons), MRCS, FRCR, PGCE Group Medical Director



This message and associated attachments is likely to contain confidential, proprietary information, trade secrets and release of any of it would prejudice substantially our commercial interests and must not be disclosed to any further parties without our prior written consent. If it has been sent to you in error please do not forward it or copy it or act upon its contents, but report it to postmaster@medica.co.uk.

Medica Group has the right lawfully to record, monitor and inspect messages between its employees and any third party. Your messages shall be subject to such lawful supervision as Medica Group deems to be necessary in order to protect its information, its interests and its reputation. Medica Group prohibits and takes steps to prevent its information systems from being used to view, store or forward offensive or discriminatory material. If this message contains such material please report it to abuse@medica.co.uk. Medica Group does not normally accept or offer business instructions via email unless prior agreements are in place. Any action that you might take upon this message might be at your own risk.

Medica Group Plc (Company No. 08497963) and Medica Reporting Ltd (Company No. 05026045) are companies registered in England and Wales. Registered Office: Sixth Floor, One Priory Square, Hastings, East Sussex, TN34 1EA. Website: www.medica.co.uk.